ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one ...
Rogue Funds, an investment management company, released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned -3.03% net of fees in the quarter. The ...
ROCKAWAY, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today announced that it has been completely vindicated in the ...
First quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quarter 2025 Net loss of $5.3 million with Adjusted EBITDA net loss improving 24% from prior-year period ...
electroCore strengthens its extensive intellectual property portfolio with issuance of two new U.S. patents, extending protection on core products and applications ROCKAWAY, N.J., March 30, 2026 ...
ROCKAWAY, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced its participation in Hacking the ...
ROCKAWAY, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness ...
About electroCore, Inc. electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy ...
GammaCore Sapphire, the newest version of gammaCore—a noninvasive vagus nerve stimulator—is now available in the United States to treat patients with migraine and episodic cluster headache ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results